Italy · Delayed Price · Currency is EUR Krystal Biotech Company Description
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 275 |
| CEO | Krish Krishnan |
Contact Details
Address: 2100 Wharton Street Pittsburgh, Delaware 15203 United States | |
| Phone | 412 586 5830 |
| Website | krystalbio.com |
Stock Details
| Ticker Symbol | 1KRYS |
| Exchange | Borsa Italiana |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Krish Krishnan | Chief Executive Officer |